Field studies are essential for both product development and regulatory approval in the agricultural sector. However, some companies underestimate the differences between commercial field development studies and regulatory studies, a mistake that can lead to duplicated trials, delayed registrations, and increased development costs.
While commercial efficacy trials are typically designed to generate agronomic insights, market positioning data, or customer-facing performance evidence, regulatory studies must meet strict scientific and compliance standards to support product registration and label claims. Companies intending to use commercial development data for regulatory submissions must understand the key considerations and therefore plan strategically from the outset to maximize investment.
Differences Between Regulatory and Commercial Field Trials
Commercial field development studies are generally more flexible in design and execution. They may focus on demonstrating product performance under real farming conditions, evaluating positioning opportunities, or supporting marketing activities.
Regulatory studies, however, are conducted under defined protocols and quality systems to ensure scientific validity, reproducibility, traceability, and auditability. Depending on the product type and jurisdiction, regulators may expect studies to comply with recognized frameworks such as Good Experimental Practice (GEP) or Good Laboratory Practice (GLP). This distinction is critical because positive agronomic results alone do not guarantee regulatory acceptance.
Regulators consider other factors such as whether study protocols followed recognized guidelines, trial conditions were appropriate, endpoints supported proposed claims, statistical analyses were robust, deviations were documented or whether raw data are auditable and reproducible.
Commercial field studies that are not designed with these requirements in mind may ultimately be unsuitable for regulatory submissions.
Regulatory Expectations Vary Across Jurisdictions
Companies also need to consider that regulatory requirements differ significantly between regions. Some authorities may accept foreign or bridging data, while others require locally generated efficacy data under specific climatic and agronomic conditions. Requirements for the number of locations, seasons, crop groupings, trial endpoints, and statistical thresholds may also vary.
For biologicals and other emerging technologies, regulatory frameworks continue to evolve globally, creating additional complexity. Developing a regulatory strategy early can help ensure field programs generate data that are usable across multiple markets and reduce the risk of conducting non-transferable studies. This is an instance where it can be very beneficial to outsource experts in product development and regulatory to ensure nothing gets missed in the development process. Investment from the beginning can save in the long run.
Best Practices for Regulatory Studies
To maximize return on investment, companies should consider the following best practices before initiating field trials:
- Define the regulatory strategy early: Identify target markets, regulatory pathways, anticipated claims, required studies, and submission timelines before trial protocols are finalized.
- Conduct data gap analysis: Review existing data to identify opportunities for waivers, bridging, or leveraging prior studies to avoid unnecessary duplication.
- Design studies to be fit-for-purpose: Determine whether studies are exploratory, commercial demonstration trials, claim-supportive studies, or intended for formal regulatory submission. Retrofitting commercial data for registration purposes after completion of study is often difficult and costly.
- Incorporate regulatory-quality practices from the outset: Where regulatory use is anticipated, studies should include documented protocols, quality oversight, validated methodologies, proper statistical plans, calibrated equipment, and secure raw data retention practices.
- Select CROs based on regulatory capability, not price alone: Companies should assess a CRO’s experience with target regulatory authorities, GEP/GLP compliance capabilities, quality assurance systems, technical expertise, and ability to meet reporting timelines.
- Manage and document deviations appropriately: Some deviations from standard guidelines may be justified, particularly for biological products. However, deviations should be scientifically justified, documented clearly, and assessed for regulatory impact.
Regulatory Studies Require a Different Operating Model
Regulatory considerations should not be treated as a downstream activity after commercial development decisions have been made. Integrating regulatory strategy into early-stage field development planning can significantly reduce time-to-market, strengthen claim substantiation, improve global data leverage, and avoid costly repeat studies.
As regulatory frameworks for agricultural biologicals and other innovative technologies continue to evolve, companies increasingly need integrated expertise across product development, regulatory affairs, and market development to ensure field trial investments deliver both commercial and regulatory value.
For timely and cost-effective launches, AgriThority® support can help with tailored regulatory and field development strategies, helping move products efficiently from development through commercialization across global markets. Reach out to the team to learn more.
